초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 09월 20일 16시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제126회 대한화학회 학술발표회 및 총회 Combining Clinical Implications from TCGA GBM and Proteomic analysis of IDH1 mutated cell-line to investigate the role of IDH1 mutation in GBM

2020년 9월 10일 16시 57분 51초
ANAL.P-287 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
10월 21일(수) 17:30~18:00
Analytical Chemistry
저자 및
Jiwon Hong, Seunghoon Back, Chaewon Kang1, Hokeun Kim, Sang-Won Lee*
Department of Chemistry, Korea University, Korea
1Korea University, Korea
Glioblastoma multiform (GBM), is an aggressive type of cancer that occurs in the brain or spinal cord. A recent genome-wide mutational analysis revealed IDH1 mutation, a common mutation found in GBM, to be associated with the increase in overall survival of GBM patients. Despite its importance, proteome research related with IDH1 mutation has not yet been systematically reported. Interestingly, the construction of the IDH1 R132H point mutated cell-line showed morphological difference over distinct time periods suggesting IDH1 mutation playing dynamic roles in the progression of GBM. Comprehensive proteome profiling was performed for three replicate sets of 6-plex TMT, labeled with wild type(WT), day1(D1) and day 6(D6) samples of two successfully built IDH1 R132H mutated U87MG cell-lines (MT9-6 and MT9-19). IMAC enrichment was conducted prior to phosphopeptide profiling with our DO-NCFC-RP/RP-MS/MS platform, resulting in average 41,603 phosphorylation sites and 51,595 distinct phosphopeptides, corresponding to 7,352 protein groups. Global profiling from DO-RPLC-MS/MS analysis resulted in 259,061 distinct peptides which correspond to 11,868 protein groups (≥2 hits), and from our results, gene ontology enrichment analysis was carried out to investigate the early and late responses of the mutation. To add clinical implication to our proteomic data, gene signatures where identified from The Cancer Genome Atlas(TCGA) GBM data, confirming the four subtypes stated in a previous study (Cancer Cell 2010). Combining clinical gene signature data and our comprehensive profiling results, we plan to construct a network model associated with collagen, which are one of the geneset that showed high correlation between clinical and protein data, expecting to find hints in the role of IDH1 mutation and its application for GBM treatment.